RESUMEN
The complexity and inter-connectedness of operating in a global world for drug product supply has become an undeniable reality, further underscored by the COVID-19 pandemic. For Post-Approval Changes (PACs) that are an inevitable part of a product's commercial life, the impact of the growing global regulatory complexity and related drug shortages has brought the Global PAC Management System to an inflection point in particular for companies that have their products marketed in many countries.This paper illustrates through data analyzed for the first time from 145,000 + PACs for 156 countries, collected by 18 global pharma companies over a 3-year period (2019-2021), how severe the problem of global regulatory complexity is. Only PACs requiring national regulatory agency (NRA) approval prior to implementation were included in the data set. 1 of the 156 country NRAs approved all submitted PACs within a period of 6 months. The 6-month timeline was chosen because it is the recommended review timeline for major changes in the WHO guidance for vaccines and biotherapeutic products. 10 out of the 156 (6%) countries had no more than 10% of the PACs reviewed and approved in > 6 months. In 33 (22%) countries more than half of the PACs took > 6 months for approval. It is rare that the same PAC is approved globally within 6 months as individual NRAs take from a few months to years (in some cases > 5 years) for their review.The global PAC management complexity has steadily grown over the past 20 years. Attempts thus far to solve this problem have not made any meaningful difference. Senior leaders and decision-makers across the interdependent components of the complex Global PAC Management System (industry and regulators) must come together and collaboratively manage the problem holistically with the objective of ensuring global drug product availability instead of continuing with distinct stakeholder or country-focused solutions, which can tend to worsen the problem.In this paper, the Chief Quality Officers (CQOs) from 18 of the largest innovator pharma companies (see Acknowledgements) are speaking with One-Voice-of-Quality for PACs (1VQ for PACs Initiative). They are recommending a set of 8 approaches to activate a holistic transformation of the Global PAC Management System. This article presents their view on the problem of global regulatory complexity for managing PACs, it's impact on continual improvement and the risk to drug product supply, as well as approaches that can help alleviate the problem.
Asunto(s)
Aprobación de Drogas , Humanos , Aprobación de Drogas/organización & administración , COVID-19 , Industria Farmacéutica/organización & administración , Industria Farmacéutica/legislación & jurisprudencia , Gestión del Cambio , Vigilancia de Productos Comercializados , SARS-CoV-2RESUMEN
This Viewpoint provides recommendations for improvements to strengthen legal obligations and decrease ambiguity for the US Food and Drug Administration regarding their reliance on voluntary preapproval withdrawal pledges.
Asunto(s)
Aprobación de Drogas , Recall de Medicamento , Vigilancia de Productos Comercializados , United States Food and Drug Administration , Aprobación de Drogas/métodos , Aprobación de Drogas/organización & administración , Estados Unidos , Recall de Medicamento/métodos , Recall de Medicamento/organización & administraciónRESUMEN
Regulatory agency interaction occurs from before a candidate drug enters clinical development and all the way to marketing approval and beyond. This paper presents ways to enable successful interaction by avoiding issues, with an emphasis on nonclinical testing aspects. Strategic thinking as to whether an early regulatory agency meeting should occur is discussed and if yes, how to make it a success by generating relevant questions with proper preparation including a robust Briefing Document. Examples of unfavourable regulatory agency feedback during meetings is given which may have been avoided. Similarly, ways for successful regulatory submission in the form of a Clinical Trials Application (CTA) in Europe or an Investigational New Drug (IND) application in the US are considered with examples of comments that can be received from regulatory agencies. At marketing application stage with submission of a Marketing Authorisation Application (MAA) in Europe and a New Drug Application (NDA) or a Biologic License Application (BLA) in the US, a key document is the Nonclinical Overview and suggested content and potential deficiencies are presented to allow avoidance of adverse regulatory agency responses and time delay. Successful regulatory agency interaction involves robust scientific thinking, proper planning and well-written documentation.
Asunto(s)
Aprobación de Drogas/organización & administración , Agencias Gubernamentales/organización & administración , Relaciones Interprofesionales , Europa (Continente) , Humanos , Aplicación de Nuevas Drogas en Investigación/organización & administración , Mercadotecnía/organización & administraciónRESUMEN
Background The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) was established in 2004. Since then, various pieces of legislation, notices, and guidelines have been issued, and the regulatory approval pathways for domestic drugs have been diversified. However, the effects of these measures have not been fully examined. We examined the impact of these measures on the approval of antineoplastic drugs and the design of pivotal clinical trials for efficacy assessment by the PMDA. Methods We collected data on the antineoplastic drugs approved by the PMDA in fiscal years 2004-2019. We extracted the approval review pathways and the pivotal clinical trial designs from the PMDA review reports, and analyzed them to identify patterns. Results In total, 387 indications in oncology were approved by the PMDA in fiscal years 2004-2019, or 365 indications excluding multiple regulatory pathways. The number of approved indications generally increased year on year (p < 0.001). The largest number of approved indications was under the Orphan Drug Designation (31%, 114/365) and this continues to increase (p < 0.001). In the 288 indications for which clinical trial data were submitted for review, the pivotal clinical trial designs changed significantly (p < 0.001) after the guideline on clinical evaluation for antineoplastic drugs was revised in 2006. Conclusion The number of indications in oncology approved by the PMDA has been increasing over the past 16 years, alongside changes in regulatory pathways. The 2006 guideline on clinical evaluation had a particular impact on pivotal clinical trial designs.
Asunto(s)
Antineoplásicos/uso terapéutico , Ensayos Clínicos como Asunto/organización & administración , Ensayos Clínicos como Asunto/estadística & datos numéricos , Aprobación de Drogas/organización & administración , Aprobación de Drogas/estadística & datos numéricos , Humanos , Japón , Producción de Medicamentos sin Interés Comercial/estadística & datos numéricosRESUMEN
The US Food and Drug Administration (FDA) is open to accepting real-world evidence (RWE) to support its assessment of medical products. However, RWE stakeholders lack a shared understanding of FDA's evidentiary expectations for the use of RWE in applications for new drugs and biologics. We conducted a systematic review of publicly available FDA approval documents from January 2019 to June 2021. We sought to quantify, by year, how many approvals incorporated RWE in any form, and the intended use of RWE in those applications. Among approvals with RWE intended to support safety and/or effectiveness, we classified whether and how those studies impacted FDA's benefit-risk considerations, whether those studies were incorporated into the product label, and the therapeutic area of the medical product. Finally, we qualified FDA's documented feedback where available. We found that 116 approvals incorporated RWE in any form, with the proportion of approvals incorporating RWE increasing each year. Of these approvals, 88 included an RWE study intended to provide evidence of safety or effectiveness. Among these 88 approvals, 65 of the studies influenced FDA's final decision and 38 were included in product labels. The 88 approvals spanned 18 therapeutic areas. FDA's feedback on RWE study quality included methodological issues, sample size concerns, omission of patient level data, and other limitations. Based on these findings, we would anticipate that future guidance on FDA's evidentiary expectations of RWE use will incorporate fit-for-purpose real-world data selection and careful attention to study design and analysis.
Asunto(s)
Productos Biológicos/uso terapéutico , Aprobación de Drogas/organización & administración , Aprobación de Drogas/estadística & datos numéricos , Medicina Basada en la Evidencia/métodos , Legislación de Medicamentos/organización & administración , Legislación de Medicamentos/estadística & datos numéricos , Humanos , Proyectos de Investigación , Medición de Riesgo/métodos , Estados Unidos , United States Food and Drug Administration/legislación & jurisprudencia , United States Food and Drug Administration/organización & administraciónAsunto(s)
Aprobación de Drogas/organización & administración , Control de Medicamentos y Narcóticos , Farmacovigilancia , África , COVID-19 , Control de Medicamentos y Narcóticos/legislación & jurisprudencia , Control de Medicamentos y Narcóticos/organización & administración , Equipos y Suministros/normas , HumanosRESUMEN
Pharmacometrics is an emerging science that interprets drug, disease, and trial information in a mathematical fashion to inform and facilitate efficient drug development and/or regulatory decisions. Pharmacometrics study is increasingly adopted in the regulatory review of new antimicrobial agents. We summarized the 31 antimicrobial agents approved by the US Food and Drug Administration (FDA) and the 26 antimicrobial agents approved by European Medicines Agency (EMA) from January 2001 to May 2019. We also reviewed recent examples of utilizing pharmacometrics to support antimicrobial agent's registration in China, including modeling and simulation methods, effects of internal/external factors on pharmacokinetic (PK) parameters, safety and efficacy evaluation in terms of exposure-response analysis, refinement of the wording of product labeling and package leaflet, and possible postmarketing clinical trial. Ongoing communication among regulator, academia, and industry regarding pharmacometrics is encouraged to streamline and facilitate the development of new antimicrobial agents. The industry can maximize its benefit in drug development through continued pharmacometrics education/training.
Asunto(s)
Antiinfecciosos/farmacología , Aprobación de Drogas/organización & administración , Antiinfecciosos/farmacocinética , China , Industria Farmacéutica/organización & administración , Europa (Continente) , Humanos , Relaciones Interprofesionales , Modelos Biológicos , Estados Unidos , United States Food and Drug Administration/organización & administración , Universidades/organización & administraciónAsunto(s)
Oftalmopatías/tratamiento farmacológico , Oftalmología , Aprobación de Drogas/organización & administración , Industria Farmacéutica/organización & administración , Oftalmopatías/fisiopatología , Humanos , Estados Unidos , United States Food and Drug Administration/organización & administraciónAsunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Aprobación de Drogas/organización & administración , Atención al Paciente , Investigación , United States Food and Drug Administration , Anticuerpos Monoclonales Humanizados/economía , Accesibilidad a los Servicios de Salud , Humanos , Resultado del Tratamiento , Estados UnidosRESUMEN
Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).This drug's approval has been highly contentious in the medical and scientific community owing to contradictory study findings and the FDA's advisory panel not recommending its approval.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Aprobación de Drogas/organización & administración , Ensayos Clínicos Controlados Aleatorios como Asunto , United States Food and Drug Administration/normas , Administración Intravenosa , Humanos , Imagen por Resonancia Magnética , Placa Amiloide/fisiopatología , Tomografía de Emisión de Positrones , Estados Unidos , United States Food and Drug Administration/organización & administraciónAsunto(s)
Antineoplásicos , Aprobación de Drogas/legislación & jurisprudencia , Legislación de Medicamentos/organización & administración , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Ensayos Clínicos como Asunto/legislación & jurisprudencia , Aprobación de Drogas/organización & administración , Desarrollo Económico , Humanos , Japón , Estudios Observacionales como Asunto/legislación & jurisprudencia , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Florian Naudet and co-authors propose a pathway involving registered criteria for evaluation and approval of new drugs.
Asunto(s)
Aprobación de Drogas/métodos , Unión Europea , Aprobación de Drogas/organización & administración , Mercadotecnía , Preparaciones FarmacéuticasRESUMEN
Microsatellite instabilityhigh/deficient mismatch repair colorectal cancer (MSIH/dMMR CRC) is a molecular subtype characterized by highfrequency mutations within DNA mismatch repair genes. Defects in the DNA mismatch repair machinery lead to subsequent frameshift mutations, resulting in the generation of frameshift peptides that serve as neoantigens. This has translated into exquisite sensitivity to immune checkpoint inhibitors (ICIs) and a significant clinical benefit from immune therapies in this patient population. The present article provides a comprehensive review of the advances in the field of immune therapies for MSIH/dMMR metastatic CRC, with a focus on the major randomized clinical trials that led to Food and Drug Administration approval of specific ICIs for this population, a detailed review of the molecular background responsible for tumor response, as well as the mechanisms of resistance to ICI therapy. Finally, ongoing investigations of other immunotherapeutic strategies to address and overcome the challenges that currently limit response and longterm response to ICIs were presented.
Asunto(s)
Neoplasias Colorrectales/tratamiento farmacológico , Reparación de la Incompatibilidad de ADN/efectos de los fármacos , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Inestabilidad de Microsatélites/efectos de los fármacos , Ensayos Clínicos como Asunto , Neoplasias Colorrectales/genética , Aprobación de Drogas/organización & administración , Resistencia a Antineoplásicos/efectos de los fármacos , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Metástasis de la Neoplasia , Estados Unidos , United States Food and Drug AdministrationRESUMEN
The posture of American regulation of medicine is negative-we assume that a new drug is unsafe and ineffective until it is proven safe and effective.1 This regulatory posture is a heuristic normative principle, a specific instance of the so-called precautionary principle in public health law.2 It is defensible, if debatable, in many ordinary circumstances.3 But like many normative heuristics, this negative posture may compel suboptimal decision-making in emergencies, where context-specific decisions must be made and a range of unique values may apply.
Asunto(s)
Toma de Decisiones/ética , Aprobación de Drogas/legislación & jurisprudencia , Urgencias Médicas , Legislación de Medicamentos/normas , Salud Pública , Aprobación de Drogas/organización & administración , Gobierno , Humanos , Legislación de Medicamentos/organización & administración , Política , Estados UnidosRESUMEN
Important breakthroughs in medical treatments have improved outcomes for patients suffering from several types of cancer. However, many oncological treatments approved by regulatory agencies are of low value and do not contribute significantly to cancer mortality reduction, but lead to unrealistic patient expectations and push even affluent societies to unsustainable health care costs. Several factors that contribute to approvals of low-value oncology treatments are addressed, including issues with clinical trials, bias in reporting, regulatory agency shortcomings and drug pricing. With the COVID-19 pandemic enforcing the elimination of low-value interventions in all fields of medicine, efforts should urgently be made by all involved in cancer care to select only high-value and sustainable interventions. Transformation of medical education, improvement in clinical trial design, quality, conduct and reporting, strict adherence to scientific norms by regulatory agencies and use of value-based scales can all contribute to raising the bar for oncology drug approvals and influence drug pricing and availability.
Asunto(s)
Aprobación de Drogas , Costos de los Medicamentos , Oncología Médica/ética , Antineoplásicos/economía , Antineoplásicos/uso terapéutico , Sesgo , COVID-19/epidemiología , Control de Costos/ética , Control de Costos/organización & administración , Control de Costos/normas , Evolución Cultural , Aprobación de Drogas/economía , Aprobación de Drogas/legislación & jurisprudencia , Aprobación de Drogas/organización & administración , Costos de los Medicamentos/ética , Costos de los Medicamentos/legislación & jurisprudencia , Humanos , Oncología Médica/economía , Oncología Médica/organización & administración , Oncología Médica/normas , Neoplasias/tratamiento farmacológico , Neoplasias/economía , Neoplasias/mortalidad , Innovación Organizacional , PandemiasRESUMEN
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19), and the resulting pandemic has caused widespread health problems and social and economic disruption. Thus far in 2021, more than 4 million people worldwide have died from COVID-19, so safe and efficacious vaccines are urgently needed to restore normal economic and social activities. According to the official guidance documents of the World Health Organization (WHO), vaccines based on four major strategies including mRNA, adenoviral vectors, inactivated viruses, and recombinant proteins have entered the stage of emergency use authorization and pre-certification evaluation. The current review summarizes these vaccines and it looks ahead to the development of additional COVID-19 vaccines in the future.
Asunto(s)
Vacunas contra la COVID-19/uso terapéutico , COVID-19/prevención & control , Aprobación de Drogas/organización & administración , Vacunas contra la COVID-19/clasificación , Humanos , ARN Mensajero/uso terapéutico , ARN Viral/uso terapéutico , Vacunas de Productos Inactivados/uso terapéutico , Organización Mundial de la SaludRESUMEN
In the last two decades, simultaneous global development of novel drugs become more common by conducting multiregional clinical trials. However, regulatory authorities of different regions often make different decisions on the approvals of the same new drugs. We would like to discuss the appropriateness of Japanese regulatory approach through a case study of quizartinib, a novel anti-leukemia drug developed in Japan. The pivotal clinical trial "QuANTUM-R" conducted in 19 countries showed a modest increase in median overall survival with quizartinib than the conventional chemotherapy. However, because several critical defects in this trial were pointed out by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA), quizartinib has not been approved in the US and Europe to date. On the contrary, the regulatory authority of Japan gave a notice of approval to quizartinib as a "standard of care", and the country becomes the sole country that granted market authorization. In our paper, we provide more detailed discussion about the methodology for scientific evaluation of the new drug.